Clinical Trial Update: Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas [Phase 1]

View source ↗

Summary

Phase 1 neoadjuvant trial combining camrelizumab with dalpiciclib for resectable head and neck squamous cell carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Camrelizumab (camrelizumab)
• Dalpiciclib (dalpiciclib)

Snippet

Sponsor: West China Hospital | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 1 | Status: RECRUITING